{
    "nctId": "NCT00893061",
    "briefTitle": "Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer",
    "officialTitle": "A Prospective, Randomized, Open-label, Multicenter Study Evaluating the Effects on Cognitive Functions of Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 44,
    "primaryOutcomeMeasure": "Changes in verbal episodic memory performance after 6 months of treatment, using the Rey Auditory Verbal Learning Test",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n* No metastatic disease\n* Meets criteria for initiating adjuvant endocrine therapy\n* Hormone receptor status:\n\n  * Estrogen receptor- and/or progesterone receptor-positive disease\n\nPATIENT CHARACTERISTICS:\n\n* Postmenopausal, defined as no menstruation for \u2265 1 year, confirmed by a measurement of FSH and 17-beta-estradiol\n* Karnofsky performance status 80-100%\n* Native speaker of French\n* Beneficiary of a French Social Security insurance plan\n* No prior cognitive disorders\n* No depression or other confirmed active psychiatric disease\n* Able to undergo the medical monitoring of the trial due to geographic, social or psychological reasons\n* No personal or family history of thromboembolic disease\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior adjuvant chemotherapy\n* No concurrent follow-up participation on another study\n* No concurrent treatment with psychotropic substances (i.e., long half life benzodiazepines, antipsychotics, anticholinesterase)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}